Structure Therapeutics(US:GPCR)2026-03-16 13:32Summary of Structure Therapeutics Conference Call on Aleniglipron Company Overview - Company: Structure Therapeutics (NasdaqGM:GPCR) - Product: Aleniglipron, an oral small molecule GLP-1 receptor agonist Key Industry Insights - Clinical Program: ACCESS II clinical program for aleniglipron - Market Context: Addressing the global obesity pandemic, with an estimated 1 billion people living with obesity by 2030 Core Findings and Data - Efficacy Results: - ACCESS II study showed a placebo-adjusted mean weight loss of 15.3% at doses of 180 mg and 240 mg after 36 weeks [5][8] - At 44 weeks, the mean weight loss was 16.3% for 180 mg and 16% for 240 mg with no signs of plateauing [8][29] - In the ACCESS open label extension, participants on 120 mg experienced a body weight loss of up to 16.2% after a median follow-up of 20 weeks [7][29] - Safety and Tolerability: - Overall adverse event (AE)-related treatment discontinuation rate was 2% in the ACCESS open label extension [9][22] - No events of drug-induced liver injury or QTc prolongation were reported across all studies [9][28] - The gastrointestinal tolerability profile improved with a starting dose of 2.5 mg, showing a lower incidence of AEs compared to higher starting doses [9][26] - Dosing Strategy: - The strategy of starting low at 2.5 mg and titrating slowly was emphasized as effective in optimizing tolerability while achieving weight loss [11][57] - Participants showed early signs of weight loss, achieving 6.4% to 6.8% weight loss after a median follow-up of 20 weeks when starting at 2.5 mg [29] Additional Insights - Future Studies: Structure Therapeutics plans to share more data from four additional studies throughout 2026, including type 2 diabetes and body composition studies [32] - Regulatory Plans: An end of phase 2 meeting with the FDA is scheduled for Q2 2026, with plans to initiate phase 3 in the second half of the year [32] - Pipeline Expansion: The company is developing an amylin program with two molecules, ACCG-2671 and ACCG-3535, to complement the GLP-1 program [33] Competitive Landscape - Differentiation: Aleniglipron is positioned as a potentially best-in-class oral GLP-1 with a strong safety profile, scalability, and combinability with other treatments [34][77] - Market Need: The company emphasizes the need for oral small molecules to meet the demand of over 100 million people in the U.S. living with obesity [35] Conclusion - Structure Therapeutics presents compelling evidence for aleniglipron's efficacy and safety, positioning it as a significant player in the obesity treatment market. The ongoing studies and strategic plans indicate a strong commitment to addressing the global obesity crisis with innovative solutions.